Login to Your Account



ALK-Abello expects $9M windfall from German drug pricing reform

By Cormac Sheridan
Staff Writer

Friday, January 3, 2014
Danish allergy vaccine firm ALK-Abello A/S said it expects to add DKK50 million to DKK52 million (US$9.1 million to US$9.5 million) to its earnings and its revenues in the coming year, because of a revision to Germany’s drug pricing regime that took effect on Jan. 1.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription